156 related articles for article (PubMed ID: 11334027)
1. Targeting of vasculature in cancer and other angiogenic diseases.
Kumar S; Li C
Trends Immunol; 2001 Mar; 22(3):129. PubMed ID: 11334027
[No Abstract] [Full Text] [Related]
2. Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignangies.
Maio M; Altomonte M; Calabro L; Fonsatti E
Front Biosci; 2001 Jun; 6():D776-84. PubMed ID: 11401781
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
4. [Development of a novel anti-cancer therapy based on targeting of tumor microvessel endothelial cells].
Tsuno H; Okaji Y; Tanaka M; Nagawa H; Takahashi K
Nihon Rinsho; 2005 Sep; 63 Suppl 9():527-33. PubMed ID: 16201576
[No Abstract] [Full Text] [Related]
5. Is it the primetime for endoglin (CD105) in the clinical setting?
Maio M; Altomonte M; Fonsatti E
Cardiovasc Res; 2006 Mar; 69(4):781-3. PubMed ID: 16448632
[No Abstract] [Full Text] [Related]
6. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies.
Matsuno F; Haruta Y; Kondo M; Tsai H; Barcos M; Seon BK
Clin Cancer Res; 1999 Feb; 5(2):371-82. PubMed ID: 10037187
[TBL] [Abstract][Full Text] [Related]
7. Expression of endoglin (CD105) in tumor blood vessels.
Seon BK
Int J Cancer; 2002 May; 99(2):310-1; author reply 312. PubMed ID: 11979450
[No Abstract] [Full Text] [Related]
8. Antibody phage display technologies with special reference to angiogenesis.
Smith J; Kontermann RE; Embleton J; Kumar S
FASEB J; 2005 Mar; 19(3):331-41. PubMed ID: 15746176
[TBL] [Abstract][Full Text] [Related]
9. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
[TBL] [Abstract][Full Text] [Related]
10. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.
Fonsatti E; Altomonte M; Nicotra MR; Natali PG; Maio M
Oncogene; 2003 Sep; 22(42):6557-63. PubMed ID: 14528280
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies.
Paleolog EM; Fava RA
Springer Semin Immunopathol; 1998; 20(1-2):73-94. PubMed ID: 9836370
[No Abstract] [Full Text] [Related]
12. Angiogenesis and metastasis marker of human tumors.
Seon BK; Takahashi N; Haba A; Matsuno F; Haruta Y; She XW; Harada N; Tsai H
Rinsho Byori; 2001 Oct; 49(10):1005-13. PubMed ID: 11769465
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies.
Tabata M; Kondo M; Haruta Y; Seon BK
Int J Cancer; 1999 Aug; 82(5):737-42. PubMed ID: 10417773
[TBL] [Abstract][Full Text] [Related]
14. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours.
Fonsatti E; Nicolay HJ; Altomonte M; Covre A; Maio M
Cardiovasc Res; 2010 Apr; 86(1):12-9. PubMed ID: 19812043
[TBL] [Abstract][Full Text] [Related]
15. CD105 is important for angiogenesis: evidence and potential applications.
Duff SE; Li C; Garland JM; Kumar S
FASEB J; 2003 Jun; 17(9):984-92. PubMed ID: 12773481
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy of targeting angiogenesis.
Hou J; Tian L; Wei Y
Cell Mol Immunol; 2004 Jun; 1(3):161-6. PubMed ID: 16219162
[TBL] [Abstract][Full Text] [Related]
17. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ
Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651
[TBL] [Abstract][Full Text] [Related]
18. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.
She X; Matsuno F; Harada N; Tsai H; Seon BK
Int J Cancer; 2004 Jan; 108(2):251-7. PubMed ID: 14639611
[TBL] [Abstract][Full Text] [Related]
19. Endoglin for tumor imaging and targeted cancer therapy.
Paauwe M; ten Dijke P; Hawinkels LJ
Expert Opin Ther Targets; 2013 Apr; 17(4):421-35. PubMed ID: 23327677
[TBL] [Abstract][Full Text] [Related]
20. [Endoglin (CD105)--a target for visualization and anti-angiogenic therapy for malignant tumors].
Smirnov IV; Gryazeva IV; Samoilovich MP; Klimovich VB
Vopr Onkol; 2015; 61(6):898-907. PubMed ID: 26995976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
